As groups representing physicians who regularly prescribe biologics, we have a unique and important perspective about the use of these medicines. While biosimilars hold tremendous promise to increase access and affordability of these advanced medicines, their availability will increase the complexity of the treatment landscape. As such, the Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest possible use of all biologics, including biosimilars, for all patients.
The Biologics Prescribers Collaborative’s mission is to ensure that physicians who prescribe complex biologic treatments are given a voice in discussions shaping policies that govern the use of biosimilars. Learn more about our four guiding principles and how we plan to achieve a unified prescriber voice.
January 16, 2017
The U.S. Food and Drug Administration (FDA) on Thursday released its final guidance for industry on the "Nonproprietary Naming of Biological Products." The move generated positive reaction from physician groups and other health professionals. Read More ›
January 12, 2017
The Biologics Prescribers Collaborative (BPC) applauds the U.S. Food and Drug Administration (FDA) for issuing final guidance calling for distinguishable names for all biologic medicines. This policy is an important win for patients and physicians because distinguishable naming is essential for pharmacovigilance, patient safety and transparency. However, as the BPC has voiced to FDA, we remain concerned with “random” suffixes called for in this guidance. Read More ›
November 9, 2016
Meaningful suffixes are important in medicine. That’s why 80% of doctors prefer them for biosimilar naming as well. The FDA is considering naming biosimilar medicines with a random code versus a more recognizable name. In a recent SERMO* poll, representing over 500 physicians across multiple specialties, 80% of physicians prefer a “meaningful suffix.” Physician groups across the country call for biosimilar names that are easily distinguished and recognized. *SERMO is the largest global social network exclusively for doctors. Read More ›
October 3, 2016
Morning Consult published an opinion editorial by Dr. Joshua Stolow of AfPA and CSRO discussing how the FDA has made great strides in developing guidelines for biosimilars, however, there still remain areas that must be addressed to ensure maximum patient safety and efficacy. Read More ›
Stay updated! For more information about the Biologics Prescribers Collaborative, please fill out the following information.